BMS’ Sotyktu secures EC approval for psoriatic arthritis

BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA). The approval was based on results from the POETYK PsA-I and POETYK PsA-II Phase III clinical trials. Safety findings for Sotyktu were generally consistent with those observed in plaque psoriasis. Credit: SaiArLawKa2 / Shutterstock.com. Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA). The approval is intended for adults with PsA who have had inadequate response or intolerance to previous disease-modifying antirheumatic drug (DMARD) therapy. Sotyktu can be used alone or…

Source: Pharmaceutical Technology